Exploring Innovative Approaches in Myasthenia Gravis and the Specialty Pharmacist’s Role in Optimizing Value-Based Treatment

This program contains a Powered by Patients™ interview.

Program Description

Myasthenia gravis (MG) is a rare neuromuscular disorder that can affect any voluntary muscle group. Though MG has a clinical course that can vary, ultimately, it is a progressive disease. Many of the traditional treatments for generalized MG have limitations related to a delayed onset of action, required monitoring, or length of treatment to mitigate adverse effects, which contribute to a significant disease burden for patients. However, as investigational therapies exploring novel mechanisms of action to modify the disease process enter the treatment landscape of MG, specialty pharmacists must be familiar with the clinical data to optimize the use of these new medications. This program will feature a Powered by Patients™ interview that captures the perspective of an individual living with MG who will share their experience with diagnosis, treatment, and decision-making with members of their care team. Equipped with knowledge of current treatment options to guide an evidence-based approach to care with a focus on emerging and recently approved therapies, specialty pharmacists will be better prepared to facilitate access to appropriate treatments to enhance the health-related quality of life of patients living with MG.

Target audience: Managed care and specialty pharmacists
Type of activity: Application
Release date: May 22, 2024
Expiration date: May 22, 2025
Learner level: Foundational
Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Explain the latest guidance on myasthenia gravis (MG) and the clinical presentation
• Explore emerging and new treatments to improve care, quality of life, and outcomes in patients with MG
• Identify the role of the specialty pharmacist in managing the symptoms of MG and interventions to provide education and support, direct appropriate referrals, and monitor treatment

Pharmacy Times Continuing Education^™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-24-145-H01-P. The activity is available for CE credit through May 22, 2025.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Faculty

Amanda Hickman, PharmD, MPH, MSCS, has the following relevant financial relationship with a commercial interest to disclose:
Other: presentation sponsored by Sanofi

James F. Howard Jr, MD, FAAN, has the following relevant financial relationships with commercial interests to disclose:
Grant/Research Support: Ad Scientiam, Alexion Pharmaceuticals, argenx BV, Cartesian Therapeutics, CDC, Duke Research Institute, NIH (NINDS, NIAMS, RDCRN-MGNet), PCORI, UCB Bioscience

Consultant: Alexion Pharmaceuticals, argenx BV, Avilar Therapeutics, F. Hoffmann-LaRoche, Horizon Therapeutics (now Amgen), Merck EMD Serono, NMD Pharma, Novartis Pharmaceuticals, Regeneron Pharma, Sanofi USA, Seismic Therapeutics, Toleranzia AB, UCB Bioscience

Advisory Board: Alexion gMG (Chair); argenx gMG Collegium (Chair); Horizon Therapeutics (now Amgen) (Chair); UCB, Rare Disease Connect Neurology, Steering Committee

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Liza Patel, PharmD, RPh; Aleksandra Thomas; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose.

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms